Induction of Targeted Necrosis with HER2-Targeted Platinum(IV) Anticancer Prodrugs
Author:
Wong Daniel Yuan Qiang
Publisher
Springer Singapore
Reference32 articles.
1. Teicher, B.A.: Molecular cancer therapeutics: will the promise be fulfilled? Mol. Cancer Ther., 7–40 (2005) 2. Shah, M.A., Schwartz, G.K.: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 7, 2168–2181 (2001) 3. Siddik, Z.H.: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265–7279 (2003) 4. Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, N.Q., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C.R., Nohadani, M., Eklund, A.C., Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., Futreal, P.A., Swanton, C.: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012) 5. Galluzzi, L., Vitale, I., Vacchelli, E., Kroemer, G.: Cell death signaling and anticancer therapy. Front. Oncol. 1 (2011)
|
|